Clinical Trial Update: Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating the combination of iparomlimab and tuvonralimab (QL1706) with lenvatinib for clear cell renal cell carcinoma, currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• Tuvonralimab (QL1706)
• iparomlimab

Snippet

Sponsor: Sun Yat-sen University | Conditions: Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma | Phase 2 | Status: RECRUITING